Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | BRAF | P15056 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.46 |
| ▸ | MALT1 | Q9UDY8 | 10/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CCR1 | P32246 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2850892 | 0.89 | NR1H4 (0.53) | NPC1RAB9ABRAFMAPTKDM4E | |
| SCHEMBL2858036 | 0.88 | BRAF (0.44) | NPC1RAB9ABRAFMAPTKDM4E | |
| SCHEMBL14539344 | 0.85 | KDM4E (0.52) | BRAFMAPTKDM4EALDH1A1NR1H4 | |
| SCHEMBL2852818 | 0.84 | NPC1 (0.50) | NPC1RAB9ABRAFMAPTKDM4E | |
| SCHEMBL2857034 | 0.83 | KDM4E (0.62) | NPC1RAB9ABRAFMAPTKDM4E | |
| SCHEMBL2853811 | 0.83 | SMN1; SMN2 (0.60) | NPC1RAB9ABRAFMAPTALDH1A1 | |
| SCHEMBL13513708 | 0.82 | KDM4E (0.53) | BRAFMAPTKDM4EALDH1A1MALT1 | |
| SCHEMBL14539343 | 0.81 | NR1H4 (0.47) | BRAFMAPTKDM4EALDH1A1NR1H4 | |
| SCHEMBL14539382 | 0.81 | BRAF (0.55) | NPC1RAB9ABRAFMAPTKDM4E | |
| SCHEMBL13513752 | 0.80 | BRAF (0.49) | NPC1RAB9ABRAFMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064690-A1 | PYRAZOLE-AMIDES AND -SULFONAMIDES | ICAGEN, INC. (US) | 2008-03-13 | — | — | US | disclosed |
| US-7223782-B2 | Pyrazole-amides and -sulfonamides | ICAGEN, INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-20050049237-A1 | Pyrazole-amides and -sulfonamides | ICAGEN, INC. (US) | 2005-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064690-A1 | PYRAZOLE-AMIDES AND -SULFONAMIDES | SCN3A, TRPV3, HCN3 | NPC1 3322/4885RAB9A 3176/4885BRAF 738/4885 |
| US-20050049237-A1 | Pyrazole-amides and -sulfonamides | SCN3A, TRPV3, HCN3 | NPC1 3322/4885RAB9A 3176/4885BRAF 738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.